03-21835. Oral Dosage Form New Animal Drugs; Etodolac  

  • Start Preamble

    AGENCY:

    Food and Drug Administration, HHS.

    ACTION:

    Final rule.

    SUMMARY:

    The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of a supplemental new animal drug application (NADA) filed by Fort Dodge Animal Health, Division of American Cyanamid Co. The supplemental NADA provides for a 500-milligram (mg) tablet size of etodolac for oral use in dogs.

    DATES:

    This rule is effective August 28, 2003.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Melanie R. Berson, Center for Veterinary Medicine (HFV-110), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, (301) 827-7540, e-mail: mberson@cvm.fda.gov.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Fort Dodge Animal Health, Division of American Cyanamid Co., P.O. Box 1339, Fort Dodge, IA 50501, filed a supplement to NADA 141-108 that provides for a 500-mg tablet size of ETOGESIC (etodolac) Tablets used for the management of pain and inflammation associated with osteoarthritis in dogs. The supplemental application is approved as of May 8, 2003, and the regulations are amended in 21 CFR 520.870 to reflect the approval. The basis of approval is discussed in the freedom of information summary.

    In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Dockets Management Branch (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. Start Printed Page 517051061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

    FDA has determined under 21 CFR 25.33(d)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

    This rule does not meet the definition of “rule” in 5 U.S.C. 804(3)(A) because it is a rule of “particular applicability.” Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801-808.

    Start List of Subjects

    List of Subjects in 21 CFR Part 520

    • Animal drugs
    End List of Subjects Start Amendment Part

    Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 520 is amended as follows:

    End Amendment Part Start Part

    PART 520—ORAL DOSAGE FORM NEW ANIMAL DRUGS

    End Part Start Amendment Part

    1. The authority citation for 21 CFR part 520 continues to read as follows:

    End Amendment Part Start Authority

    Authority: 21 U.S.C. 360b.

    End Authority
    [Amended]
    Start Amendment Part

    2. Section 520.870 Etodolac is amended in paragraph (a) by removing “150 or 300” and by adding in its place “150, 300, or 500”.

    End Amendment Part Start Signature

    Dated: August 13, 2003.

    Steven D. Vaughn,

    Director, Office of New Animal Drug Evaluation, Center for Veterinary Medicine.

    End Signature End Supplemental Information

    [FR Doc. 03-21835 Filed 8-27-03; 8:45 am]

    BILLING CODE 4160-01-S

Document Information

Effective Date:
8/28/2003
Published:
08/28/2003
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
03-21835
Dates:
This rule is effective August 28, 2003.
Pages:
51704-51705 (2 pages)
PDF File:
03-21835.pdf
CFR: (1)
21 CFR 520.870